Abstract
Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Current Drug Targets
Title: Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Volume: 7 Issue: 7
Author(s): Martin K. Pos, Peter J.F. Henderson, Roslyn M. Bill, Melissa H. Brown, Nicholas G. Rutherford, John O'Reilly, Ian T. Paulsen, Ronald A. Skurray, Richard B. Herbert, Kate Langton, Karl Walraven, Patrick Butaye, Massoud Saidijam, Scott Morrison, Johan Meuller, Gerda Szakonyi, Kim E. Bettaney, Alison Ward, Sarah L. Palmer, Christopher J. Hoyle, Zhiqiang Xu, Qinghu Ren and Giulia Benedetti
Affiliation:
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Abstract: Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Export Options
About this article
Cite this article as:
Pos K. Martin, Henderson J.F. Peter, Bill M. Roslyn, Brown H. Melissa, Rutherford G. Nicholas, O'Reilly John, Paulsen T. Ian, Skurray A. Ronald, Herbert B. Richard, Kate Langton , Karl Walraven , Patrick Butaye , Saidijam Massoud, Scott Morrison , Meuller Johan, Szakonyi Gerda, Bettaney E. Kim, Ward Alison, Palmer L. Sarah, Hoyle J. Christopher, Xu Zhiqiang, Ren Qinghu and Benedetti Giulia, Microbial Drug Efflux Proteins of the Major Facilitator Superfamily, Current Drug Targets 2006; 7 (7) . https://dx.doi.org/10.2174/138945006777709575
DOI https://dx.doi.org/10.2174/138945006777709575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Transcriptomic Biomarkers in Cancer Diagnosis, Prognosis and Therapy Monitoring (Guest Editor: Monica Neagu)]
Recent Patents on Biomarkers Assessment of a Novel Vitamin D<sub>3</sub> Formulation with Nanostructured Lipid Carriers for Transdermal Delivery
Current Drug Delivery EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Osteogenic Differentiation of Orofacial Tissue-Derived Mesenchymal Stem Cells- A Review
Current Tissue Engineering (Discontinued) Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Array-Based Approaches for the Identification of Epigenetic Silenced Tumor Suppressor Genes
Current Genomics The Role of Stress Proteins in Prostate Cancer
Current Genomics Bioaccessibility of Bioactive Compounds and Prebiotic Properties of Fruit and Vegetable By-products - A Mini Review
Current Bioactive Compounds Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets